Achilles Therapeutics PLC ADR (ACHL)vsargenx NV ADR (ARGX)
ACHL
Achilles Therapeutics PLC ADR
$1.48
0.00%
HEALTHCARE · Cap: $63.22M
ARGX
argenx NV ADR
$891.32
+5.82%
HEALTHCARE · Cap: $56.45B
Smart Verdict
WallStSmart Research — data-driven comparison
ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ACHL
Avoid32
out of 100
Grade: F
ARGX
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACHL.
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$891.32
$1313.01 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 188.4x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ACHL
The strongest argument for ACHL centers on Price/Book, Debt/Equity.
Bull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bear Case : ACHL
The primary concerns for ACHL are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Key Dynamics to Monitor
ACHL profiles as a value stock while ARGX is a growth play — different risk/reward profiles.
ACHL carries more volatility with a beta of 1.25 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 32/100), backed by strong 31.4% margins and 62.6% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Achilles Therapeutics PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?